Events

The Center for Innovation Policy at Duke Law co-hosted this event with Duke Science & Society, the Duke Global Health Institute, the Georgetown Law O’Neill Institute for National and Global Health, the Harvard Petrie-Flom Center for Bioethics, the Stanford Law Center for aw and the Biosciences, the UNC HIV Cure Center, and the Yale School of Public Health.

Ten months into the pandemic, we are making rapid progress toward developing a safe and effective COVID-19 vaccine, with several vaccines in Phase 3 trials in the US alone. Despite this remarkable speed, concerned citizens and members of the medical and public health communities naturally have questions: What does it mean about overall safety and effectiveness that some projects have been paused to ensure the safety and health of vaccine trial participants? Who has been included in the trial process, and how representative are they of our society? When the first vaccines are found to be safe and effective, how effective can we expect them to be, based on current indications? Join the speakers, who are overseeing COVID-19 vaccine trials for Moderna and Pfizer, in a discussion of how the COVID-19 vaccine trials are progressing in the U.S., what current indications are about their safety and efficacy, and when we can expect initial approvals for early or limited use.

Panelists:

• Cindy Gay, M.D., M.P.H., Principal Investigator, University of North Carolina site of the Moderna SARS-COV-2 vaccine trial, Associate Professor of Medicine, Division of Infectious Diseases; Medical Director, UNC HIV Cure Center
• Chip Walter, M.D., Principal Investigator, Duke University site of the Pfizer SARS-COV-2 vaccine trial, Professor of Pediatrics, Affiliate, Duke Global Health Institute, Member in the Duke Clinical Research Institute, Member of the Duke Human Vaccine Institute; 

Moderator:

• Nita Farahany, J.D., Ph.D., Director, Duke Initiative for Science & Society, Duke University; Professor of Law and Philosophy, Duke University

Watch The Recording